Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 130 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Moderate Renal Impairment Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function

NCT04471337
View directory record Official record
Conditions
Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions
BAY1817080
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 9, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment

NCT01120314
View directory record Official record
Conditions
Renal Impairment
Interventions
OTAMIXABAN (XRP0673)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
4
States / cities
Miami Gardens, Florida • Orlando, Florida • Saint Paul, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Sep 9, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

NCT03636269
View directory record Official record
Conditions
Uremic Pruritus
Interventions
CR845 0.5 mcg/kg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Chula Vista, California • Fountain Valley, California • Northridge, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Sep 9, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment

NCT05704556
View directory record Official record
Conditions
Pain
Interventions
VX-548
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
7
States / cities
DeLand, Florida • Miami, Florida • St. Petersburg, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Sep 9, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

NCT02836873
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
20 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Fresno, California • La Palma, California • Lincoln, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 9, 2026, 9:03 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Clofutriben Pharmacokinetics in Patients With Impaired Renal Function

NCT07227922
View directory record Official record
Conditions
Moderate Renal Impairment
Interventions
12mg clofutriben
Drug
Lead sponsor
Sparrow Pharmaceuticals
Industry
Eligibility
18 Years to 83 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 9, 2026, 9:03 PM EDT
Completed Phase 4 Interventional

A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment

NCT02864199
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
12
States / cities
Birmingham, Alabama • Kansas City, Kansas • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Sep 9, 2026, 9:03 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

NCT01359579
View directory record Official record
Conditions
Renal Impairment
Interventions
varespladib methyl
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Sep 9, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

NCT01064414
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
25 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
26
States / cities
Concord, California • Fountain Valley, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Sep 9, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Safety & Tolerability Study of CTP-499 in Patients With Moderate Chronic Kidney Disease

NCT01460199
View directory record Official record
Conditions
Stage 3 Chronic Kidney Disease
Interventions
CTP-499, placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
3
States / cities
Costa Mesa, California • Garden Grove, California • Tustin, California
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Sep 9, 2026, 9:03 PM EDT
Terminated Phase 3 Interventional Results available

Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy

NCT00108485
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Hyperlipidemia
Interventions
Extended release niacin, Placebo
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Sep 9, 2026, 9:03 PM EDT
Completed No phase listed Observational Results available

Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist

NCT00744939
View directory record Official record
Conditions
Fibrosis, Kidney Failure, Renal Insufficiency
Interventions
Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Drug
Lead sponsor
Bayer
Industry
Eligibility
2 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
26
States / cities
Phoenix, Arizona • Chula Vista, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Sep 9, 2026, 9:03 PM EDT
Completed Not applicable Interventional

Aerobic Training and Arterial Stiffness in Chronic Kidney Disease (CKD) Patients

NCT01399489
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension, Diabetes
Interventions
Exercise training
Behavioral
Lead sponsor
Springfield College
Other
Eligibility
35 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Sep 9, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects

NCT02634437
View directory record Official record
Conditions
Renal Function
Interventions
Ulipristal acetate
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 9, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

NCT01363011
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, COBI, ATV, DRV, NRTI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Sep 9, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)

NCT03259087
View directory record Official record
Conditions
Renal Impairment
Interventions
MK-3866
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Sep 9, 2026, 9:03 PM EDT
Active, not recruiting Not applicable Interventional

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

NCT01047735
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
Procedure · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 9, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

NCT03281538
View directory record Official record
Conditions
Uremic Pruritus
Interventions
CR845
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Chula Vista, California • El Centro, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 9, 2026, 9:03 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment

NCT00984113
View directory record Official record
Conditions
Renal Impairment
Interventions
Elinogrel
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 9, 2026, 9:03 PM EDT
Completed Not applicable Interventional

Efficacy and Safety of the DASH Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study

NCT02059811
View directory record Official record
Conditions
Hypertension, Chronic Kidney Disease
Interventions
DASH Diet, Control Diet
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Sep 9, 2026, 9:03 PM EDT
Completed Phase 1 Interventional

Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction

NCT01444872
View directory record Official record
Conditions
Heart Failure, Kidney Disease
Interventions
TRV120027, Normal Saline
Drug
Lead sponsor
Trevena Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Orlando, Florida • Minneapolis, Minnesota • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2012 · Synced Sep 9, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

NCT02413398
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin 10 mg, Matching Placebo for Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 74 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
27
States / cities
Huntsville, Alabama • Burbank, California • Chula Vista, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 9, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

NCT01620489
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
53
States / cities
Concord, California • La Jolla, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 9, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)

NCT00500682
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Placebo, AST-120
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
41
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Alhambra, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 9, 2026, 9:03 PM EDT